The US Patent and Trademark Office has issued Patent number 8,324,266, titled “Compositions, Methods & Systems for Respiratory Delivery of Two or More Active Agents,” to Pearl Therapeutics. The patent covers formulation methods using the company's co-suspension technology in metered-dose inhalers (MDIs). Pearl says that "the technology effectively prevents the … [Read more...] about New patent for Pearl Therapeutics
News
Ken Cunningham new Non-executive Chairman of Prosonix
Prosonix has announced that Ken Cunningham will replace Jim Philips as Non-executive Chairman. Cunningham, who is also Chair of the company's scientific advisory board, is a former CEO of Skyepharma. He has been a member of the board of Prosonix since September 2011. Phillips, who is retiring from the board of directors, said, “After five years chairing Prosonix … [Read more...] about Ken Cunningham new Non-executive Chairman of Prosonix
Bespak to manufacture nicotine inhaler for Nicoventures
According to Consort Medical, Nicoventures, a subsidiary of the British American Tobacco Group, has awarded a contract to Consort's Bespak Division "for the supply of an innovative nicotine inhalation product for use as a safer alternative to smoking." In November 2011, Bespak announced the award of a development contract for scale-up of the "cigarette-like device." … [Read more...] about Bespak to manufacture nicotine inhaler for Nicoventures
Lightlake appoints Kevin Pollack as CFO
Lightlake Therapeutics, which is developing intranasal naloxone to treat eating disorders, has announced the appointment of board member Kevin Pollack as Chief Financial Officer. Pollack joined the board of directors in April 2012. Lightlake Chief Executive Roger Crystal said, "It has been a privilege to work with Kevin since he joined our Board and when we look to … [Read more...] about Lightlake appoints Kevin Pollack as CFO
Hovione and Solvias to collaborate on co-crystals
Inhalation and particle engineering specialist Hovione and Swiss chemical development company Solvias have announced an agreement to collaborate on development and manufacturing of co-crystallized drugs. According to Hovione, "This strengthens Hovione's expertise and experience in overcoming drug delivery challenges and also the supply of GMP materials from phase I to … [Read more...] about Hovione and Solvias to collaborate on co-crystals
FDA issues letter to Alcon over Patanase marketing
The FDA issued a letter to Alcon dated November 13, 2012 regarding a sales aid that the agency says overstates the efficacy of Alcon's Patanase olopatadine hydrochloride nasal spray. In the four-page letter, the agency cites numerous examples of what it says are overstatements of the product's onset of action and the duration of relief and then requests that Alcon … [Read more...] about FDA issues letter to Alcon over Patanase marketing
Next Breath announces successful FDA inspection
Maryland-based CRO Next Breath, which specializes in OINDP analysis, has announced that an October 15, 2012 GMP inspection by the FDA found the company's Baltimore facility to be compliant. The inspection resulted in no Form 483 and no observations. Earlier this year, the World Health Organization (WHO) accredited Next Breath as a testing facility for nasal spray … [Read more...] about Next Breath announces successful FDA inspection
Presspart hires Ameet Sule to head its Inhalation Product Technology Centre
OINDP component manufacturer Presspart has announced the appointment of Ameet Sule as Director of its new Inhalation Product Technology Centre (IPTC) in Blackburn, UK. Sule, who was most recently Director of Pulmonary Research at Lupin, will head the IPTC beginning January 15, 2013. He has almost 20 years of experience with respiratory delivery devices, formulations, … [Read more...] about Presspart hires Ameet Sule to head its Inhalation Product Technology Centre
Unigene says EMA recommendation against calcitonin nasal sprays “catastrophic”
Fortical salmon calcitonin nasal spray manufacturer Unigene says that it is in danger of running out of cash before the end of the first quarter of 2013, due in part to the EMA's July 2012 warning against the use of calcitonin nasal sprays. Unigene President and CEO Ashleigh Palmer said, "The impact of the EMA’s recommendation represents a devastating setback and … [Read more...] about Unigene says EMA recommendation against calcitonin nasal sprays “catastrophic”
Study shows Aradigm’s Lipoquin protects against plague in mice
A study by scientists from the UK Defence Science and Technology Laboratory (Dstl) showed that a single dose of Aradigm's Lipoquin liposomal ciprofloxacin administered through the nose fully protected mice exposed to an aerosolized "lethal dose" of Yersinia pestis. Inhaled aerosolized Lipoquin provided 70% protection, while untreated mice and those given a single dose … [Read more...] about Study shows Aradigm’s Lipoquin protects against plague in mice